Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Adial Pharmaceuticals Inc (ADIL)

Adial Pharmaceuticals Inc (ADIL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Adial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for Veterans GlobeNewswire - Tue Mar 24, 8:07AM CDT

GLEN ALLEN, Va., March 24, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on the development...

ADIL : 1.7900 (+4.68%)
Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update GlobeNewswire - Fri Mar 6, 7:00AM CST

GLEN ALLEN, Va., March 06, 2026 (GLOBE NEWSWIRE) --  Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...

ADIL : 1.7900 (+4.68%)
Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement GlobeNewswire - Tue Mar 3, 7:17AM CST

GLEN ALLEN, Va., March 03, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on the development...

ADIL : 1.7900 (+4.68%)
Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement GlobeNewswire - Tue Feb 24, 8:00AM CST

GLEN ALLEN, Va., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. ( NASDAQ: ADIL ) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...

ADIL : 1.7900 (+4.68%)
Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One GlobeNewswire - Mon Feb 23, 7:30AM CST

GLEN ALLEN, Va., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. ( NASDAQ: ADIL ) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...

ADIL : 1.7900 (+4.68%)
Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference GlobeNewswire - Tue Feb 17, 8:00AM CST

GLEN ALLEN, Va., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. ( NASDAQ: ADIL ) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...

ADIL : 1.7900 (+4.68%)
Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04 GlobeNewswire - Wed Feb 4, 8:35AM CST

GLEN ALLEN, Va., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. ( NASDAQ: ADIL ) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...

ADIL : 1.7900 (+4.68%)
Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement GlobeNewswire - Tue Feb 3, 3:05PM CST

GLEN ALLEN, Va., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL)  (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...

ADIL : 1.7900 (+4.68%)
Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045 GlobeNewswire - Wed Jan 14, 8:00AM CST

GLEN ALLEN, Va., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. ( NASDAQ: ADIL ) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...

ADIL : 1.7900 (+4.68%)
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds GlobeNewswire - Wed Nov 26, 2025

GLEN ALLEN, Va., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...

ADIL : 1.7900 (+4.68%)

Barchart Exclusives

This Dividend King Is Down 26%. When Will It Bounce Back? Barchart - 1 hour ago
Abbott Laboratories is down 26% from its 52-week high due to a soft quarter. With 54 consecutive years of dividend hikes and guidance calling for mid-single-digit organic sales growth plus 10% EPS expansion, the Dividend King seems discounted, but the question is, can it rebound? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.